An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis

(2011) Raimundo Fernando Bezares et al.   LEUKEMIA & LYMPHOMA

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories

(2010) M. Fiegl et al.   ANNALS OF ONCOLOGY

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches

(2010) Vicki A. Morrison   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

(2010) M. D. Danese et al.   BLOOD

State of the art treatment of chronic lymphocytic leukaemia

(2010) Michael Hallek et al.   BLOOD REVIEWS

Chronic lymphocytic leukemia: planning for an aging population

(2010) John G Gribben   Expert Review of Anticancer Therapy

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

Rediscovering alemtuzumab: current and emerging therapeutic roles

(2009) John G. Gribben et al.   BRITISH JOURNAL OF HAEMATOLOGY

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

(2009) A Cortelezzi et al.   LEUKEMIA

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

(2009) A Österborg et al.   LEUKEMIA

Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab

(2008) A. Nosari et al.   HAEMATOLOGICA